Research peptide · BI 456906
Survodutide 10 mg
Survodutide 10 mg GLP-1 and glucagon receptor research material. Select 1, 2 or 3 vials for 10, 20 or 30 mg total content.
Research peptide · BI 456906
Survodutide 10 mg GLP-1 and glucagon receptor research material. Select 1, 2 or 3 vials for 10, 20 or 30 mg total content.
Research peptide · BI 456906
Survodutide 10 mg GLP-1 and glucagon receptor research material. Select 1, 2 or 3 vials for 10, 20 or 30 mg total content.
No reviews yet. Be the first to share your experience.
No reviews yet. Be the first to share your experience.
/ vial
Order today → Delivery Thu, Nov 12 – Fri, Nov 20 to United States
/ vial
Order today → Delivery Thu, Nov 12 – Fri, Nov 20 to United States
Independently verified quality
3,000+
satisfied researchers
99.43%
Avg. purity 2026
4.8 ★
ProvenExpert
99.43%
Avg. purity 2026
4.8 ★
ProvenExpert
3,000+ satisfied researchers
Survodutide 10 mg - 1 Vial vial + 2 ml BAC water → concentration:
Per unit (10 IU)
0.50 mg
Research details
Survodutide, also designated BI 456906, is described in published research as a dual agonist at GLP-1 and glucagon receptors. It is distinct from GIP-containing compounds. This receptor profile is the relevant molecular identity for research classification.
Each vial contains 10 mg of Survodutide. The material is supplied for research use only and is not presented as a medicine, treatment or product for human or animal use.
Survodutide combines GLP-1 receptor agonism with glucagon receptor agonism. This distinguishes its research profile from the GIP/GLP-1 combination associated with tirzepatide and from compounds that target three receptors. The receptor combination is central to the published metabolic research on BI 456906.
Published phase 2 trials examined survodutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH). Those trials used defined investigational formulations and controlled protocols. Their clinical findings do not establish equivalence, safety or efficacy for the research material offered on this page.
One vial provides 10 mg total content, two vials provide 20 mg and three vials provide 30 mg. Each individual vial remains 10 mg.
Strength identifies the content of a vial. Pack count identifies the number of separately supplied vials selected for the research inventory.
Survodutide clinical trial in the New England Journal of Medicine
Dual GLP-1 and glucagon receptor agonist.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.43% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
Survodutide, also known as BI 456906, is described as a dual GLP-1 and glucagon receptor agonist.
Independently verified quality
3,000+
satisfied researchers
99.43%
Avg. purity 2026
4.8 ★
ProvenExpert
99.43%
Avg. purity 2026
4.8 ★
ProvenExpert
3,000+ satisfied researchers
Survodutide 10 mg - 1 Vial vial + 2 ml BAC water → concentration:
Per unit (10 IU)
0.50 mg
Research details
Survodutide, also designated BI 456906, is described in published research as a dual agonist at GLP-1 and glucagon receptors. It is distinct from GIP-containing compounds. This receptor profile is the relevant molecular identity for research classification.
Each vial contains 10 mg of Survodutide. The material is supplied for research use only and is not presented as a medicine, treatment or product for human or animal use.
Survodutide combines GLP-1 receptor agonism with glucagon receptor agonism. This distinguishes its research profile from the GIP/GLP-1 combination associated with tirzepatide and from compounds that target three receptors. The receptor combination is central to the published metabolic research on BI 456906.
Published phase 2 trials examined survodutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH). Those trials used defined investigational formulations and controlled protocols. Their clinical findings do not establish equivalence, safety or efficacy for the research material offered on this page.
One vial provides 10 mg total content, two vials provide 20 mg and three vials provide 30 mg. Each individual vial remains 10 mg.
Strength identifies the content of a vial. Pack count identifies the number of separately supplied vials selected for the research inventory.
Survodutide clinical trial in the New England Journal of Medicine
Dual GLP-1 and glucagon receptor agonist.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.43% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
Survodutide, also known as BI 456906, is described as a dual GLP-1 and glucagon receptor agonist.
